V-ATPase D2 inhibitors represent a chemical class designed to selectively target and inhibit the activity of the V-ATPase D2 subunit, a crucial component of the vacuolar-type H+-ATPase (V-ATPase) enzyme. V-ATPases are ATP-driven proton pumps found in the membranes of various intracellular compartments and in the plasma membrane of many eukaryotic cells. They play a vital role in regulating the acidification of intracellular compartments, such as lysosomes, endosomes, and the Golgi apparatus. The inhibition of the D2 subunit by these chemicals disrupts the normal function of V-ATPase, leading to altered proton pumping and intracellular pH balance. This selective inhibition is significant because the D2 subunit is specifically involved in the assembly and operation of the V-ATPase complex, and its modulation can have profound effects on cellular processes dependent on acidification.
V-ATPase D2 inhibitors is characterized by their ability to interact with the D2 subunit of the V-ATPase complex. These inhibitors are typically small molecules that can penetrate cellular membranes to reach intracellular targets. The binding of these chemicals to the D2 subunit affects the structural integrity and function of the V-ATPase complex. This interaction specifically inhibits the proton pump mechanism of the enzyme, resulting in reduced acidification of intracellular compartments. The precise binding sites and mechanism of inhibition can vary among different inhibitors in this class, with some binding to allosteric sites and others interfering directly with the active sites of the D2 subunit. The inhibition of V-ATPase D2 can influence various cellular processes, including protein degradation, receptor-mediated endocytosis, and intracellular signaling pathways. The ability to selectively target the D2 subunit is a defining feature of this class, allowing for specific modulation of V-ATPase activity without affecting other ATPases or cellular processes not directly related to the V-ATPase function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar type H+-ATPase (V-ATPase). It binds to the V0 subunit of the enzyme, preventing proton transport and thereby disrupting acidification of intracellular compartments such as lysosomes and endosomes. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A, similar to Bafilomycin A1, targets the V0 subunit of V-ATPase. It inhibits proton pumping activity, leading to increased pH in acidic vesicles and altered endocytic and autophagic pathways. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Though primarily known as a proton pump inhibitor for gastric acid-related disorders, Omeprazole also exhibits inhibitory effects on V-ATPase. It can indirectly influence the V-ATPase functionality by altering cellular proton dynamics. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
Loxistatin, or E-64-d, is a cysteine protease inhibitor that can indirectly affect V-ATPase activity. By inhibiting lysosomal proteases, it may impact the lysosomal function and thus the requirement for V-ATPase activity, indirectly modulating its action. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin, an Hsp90 inhibitor, can indirectly influence V-ATPase activity. By inhibiting Hsp90, it affects the stability of several client proteins, potentially including those involved in the regulation or formation of V-ATPase, thus modulating its activity. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A has been observed to indirectly affect V-ATPase activity. It may modulate the expression or stability of proteins involved in V-ATPase assembly or regulation, thereby influencing the enzyme's function. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine has been found to accumulate in acidic vesicles and raise their pH, indirectly inhibiting V-ATPase activity by disrupting the proton gradient necessary for its function. | ||||||